Literature DB >> 34520898

Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

J I Aguirre1, E J Castillo2, D B Kimmel3.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event affecting patients with cancer and patients with osteoporosis who have been treated with powerful antiresorptives (pARs) or angiogenesis inhibitors (AgIs). pARs, including nitrogen-containing bisphosphonates (N-BPs; e.g., zoledronic acid, alendronate) and anti-RANKL antibodies (e.g., denosumab), are used to manage bone metastases in patients with cancer or to prevent fragility fractures in patients with osteoporosis. Though significant advances have been made in understanding MRONJ, its pathophysiology is still not fully elucidated. Multiple species have been used in preclinical MRONJ research, including the rat, mouse, rice rat, rabbit, dog, sheep, and pig. Animal research has contributed immensely to advancing the MRONJ field, particularly, but not limited to, in developing models and investigating risk factors that were first observed in humans. MRONJ models have been developed using clinically relevant doses of systemic risk factors, like N-BPs, anti-RANKL antibodies, or AgIs. Specific local oral risk factors first noted in humans, including tooth extraction and inflammatory dental disease (e.g., periodontitis, periapical infection, etc.), were then added. Research in rodents, particularly the rat, and, to some extent, the mouse, across multiple laboratories, has contributed to establishing multiple relevant and complementary preclinical models. Models in larger species produced accurate clinical and histopathologic outcomes suggesting a potential role for confirming specific crucial findings from rodent research. We view the current state of animal models for MRONJ as good. The rodent models are now reliable enough to produce large numbers of MRONJ cases that could be applied in experiments testing treatment modalities. The course of MRONJ, including stage 0 MRONJ, is characterized well enough that basic studies of the molecular or enzyme-level findings in different MRONJ stages are possible. This review provides a current overview of the existing models of MRONJ, their more significant features and findings, and important instances of their application in preclinical research.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; BRONJ; Bisphosphonates; MRONJ; ONJ; Preclinical studies; RANKL-inhibitors

Mesh:

Substances:

Year:  2021        PMID: 34520898      PMCID: PMC8743993          DOI: 10.1016/j.bone.2021.116184

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  308 in total

1.  Osteonecrosis of the jaw related to bevacizumab.

Authors:  Cherry L Estilo; Monica Fornier; Azeez Farooki; Diane Carlson; George Bohle; Joseph M Huryn
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

2.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

3.  Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid.

Authors:  Ji-Su Oh; Su-Gwan Kim
Journal:  Braz Oral Res       Date:  2017-12-07

4.  Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients.

Authors:  Mehmet Ali-Erdem; Abdulkadir Burak-Cankaya; Sabri Cemil-Isler; Sabit Demircan; Merva Soluk; Cetin Kasapoglu; Cuneyt Korhan-Oral
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2011-11-01

5.  The feasibility of locating the affected bone of BRONJ with indocyanine green.

Authors:  Cheng-Wan Xia; Jiong-Ru Pan; Lei Fan; Qi Xiao; Yumei Pu; Yu-Xin Wang
Journal:  Oral Dis       Date:  2020-02-21       Impact factor: 3.511

6.  Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ).

Authors:  Ioannis Gkouveris; Danny Hadaya; Akrivoula Soundia; Olga Bezouglaia; Yee Chau; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2019-04-03       Impact factor: 4.398

7.  Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats.

Authors:  Mariana M Moreira; Vivian Bradaschia-Correa; Natasha D M Marques; Lorraine Braga Ferreira; Victor E Arana-Chavez
Journal:  Microsc Res Tech       Date:  2014-08-07       Impact factor: 2.769

8.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

9.  Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw.

Authors:  Ji Young Park; Hyun A Heo; Suhyun Park; Sung Woon Pyo
Journal:  J Periodontal Implant Sci       Date:  2020-03-19       Impact factor: 2.614

10.  Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.

Authors:  Naomi Adachi; Yasunori Ayukawa; Noriyuki Yasunami; Akihiro Furuhashi; Mikio Imai; Koma Sanda; Ikiru Atsuta; Kiyoshi Koyano
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

View more
  5 in total

1.  Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.

Authors:  Kathrin Becker; Robert Kerberger; Giulia Brunello; Joel Rockhoff; Nicole Rauch; Frank Schwarz
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

2.  Teledentistry as a Supportive Tool for Dentists in Diagnosing MRONJ in Northern Cyprus.

Authors:  Mujgan Firincioglulari; Kaan Orhan
Journal:  Biomed Res Int       Date:  2021-12-29       Impact factor: 3.411

Review 3.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

Review 4.  How zoledronic acid improves osteoporosis by acting on osteoclasts.

Authors:  Biao Wang; Yi Zhan; Liang Yan; Dingjun Hao
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

5.  Structural insights into the binding of zoledronic acid with RANKL via computational simulations.

Authors:  Ruijie Wang; Wenjie Zhang; Hailong Ma; Duohong Zou; Zhiyuan Zhang; Shaoyi Wang
Journal:  Front Mol Biosci       Date:  2022-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.